HC Wainwright Analysts Increase Earnings Estimates for MBOT

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Microbot Medical to ($0.07) from ($0.09) and maintains a Buy rating with a $12.00 price target.
• Street consensus is more conservative, showing a Moderate Buy with a consensus price target of $7.50 and a full‑year 2026 EPS estimate of ($0.71), versus HC Wainwright's FY2026 estimate of ($0.32).
• MBOT trades around $2.39 (1‑year range $1.60–$4.67) with a market cap of about $160.5M, and it posted last quarter EPS of ($0.04), beating estimates by $0.02.

Microbot Medical Inc. (NASDAQ:MBOT - Free Report) - Equities research analysts at HC Wainwright boosted their Q1 2026 earnings per share estimates for shares of Microbot Medical in a research note issued on Tuesday, April 14th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.07) per share for the quarter, up from their previous forecast of ($0.09). HC Wainwright currently has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Microbot Medical's current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical's Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.32) EPS.

A number of other research analysts also recently issued reports on MBOT. B. Riley Financial started coverage on Microbot Medical in a report on Tuesday, February 10th. They set a "buy" rating on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Microbot Medical in a report on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $7.50.

Microbot Medical Price Performance

MBOT stock opened at $2.39 on Thursday. Microbot Medical has a 1-year low of $1.60 and a 1-year high of $4.67. The business has a fifty day moving average price of $2.37 and a 200-day moving average price of $2.32. The stock has a market capitalization of $160.51 million, a P/E ratio of -8.24 and a beta of 1.19.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings data on Sunday, March 22nd. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Cornerstone Advisory LLC bought a new position in shares of Microbot Medical during the 3rd quarter valued at $30,000. American Century Companies Inc. bought a new position in shares of Microbot Medical during the 2nd quarter valued at $32,000. Zacks Investment Management bought a new position in shares of Microbot Medical during the 3rd quarter valued at $33,000. Man Group plc bought a new position in shares of Microbot Medical during the 4th quarter valued at $35,000. Finally, Squarepoint Ops LLC bought a new position in shares of Microbot Medical during the 3rd quarter valued at $37,000. 16.30% of the stock is owned by institutional investors.

About Microbot Medical

Microbot Medical Inc NASDAQ: MBOT is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.